Spire Healthcare Group (LON:SPI) Stock Price Down 17.8% After Analyst Downgrade

Spire Healthcare Group plc (LON:SPI)’s share price traded down 17.8% during mid-day trading on Thursday after Deutsche Bank Aktiengesellschaft lowered their price target on the stock from GBX 320 to GBX 300. Deutsche Bank Aktiengesellschaft currently has a buy rating on the stock. Spire Healthcare Group traded as low as GBX 169 ($2.18) and last traded at GBX 184.60 ($2.39). 5,565,048 shares changed hands during mid-day trading, an increase of 727% from the average session volume of 672,747 shares. The stock had previously closed at GBX 224.50 ($2.90).

Spire Healthcare Group Price Performance

The company has a 50 day moving average price of GBX 227.28 and a 200-day moving average price of GBX 229.74. The company has a quick ratio of 0.74, a current ratio of 0.70 and a debt-to-equity ratio of 62.25. The company has a market cap of £711.58 million, a price-to-earnings ratio of 25.22, a P/E/G ratio of 1.06 and a beta of 0.96.

Spire Healthcare Group (LON:SPI) last released its quarterly earnings data on Thursday, March 6th. The company reported GBX 8.80 ($0.11) earnings per share (EPS) for the quarter. Spire Healthcare Group had a return on equity of 3.82% and a net margin of 1.96%. As a group, equities research analysts predict that Spire Healthcare Group plc will post 15.6634747 EPS for the current fiscal year.

About Spire Healthcare Group

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.